STUDresearch · Non-peptide
MTX-325
Also known as
MTX325 · MTX 325 · MTX115325 · MTX-115325 · Mission MTX325 · USP30 inhibitor MTX-325
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Non-peptide
Niche talk
Systemic
Oral
Mitochondrial & metabolic compounds
Systemic oral small molecule.
What people say
MTX-325, also called MTX115325, is an investigational oral small-molecule USP30 inhibitor in a Parkinson's disease program. It is not Urolithin A, MOTS-c or a peptide.
Doses people talk about
Study-arm strengths do not establish safety, efficacy, frequency or an off-label longevity dose. The 50 mg placebo description is not active MTX325.
How it may feel
No credible direct biohacker diary or posted trial participant feel curve was identified. Pipeline discussion and animal findings cannot supply a week-by-week human experience.
Registered Phase 1 active arms1.5–100 mg oral; 20 mg PD arm
Parts 1–4 list active capsule strengths from 1.5 to 100 mg; the PET and mild-to-moderate Parkinson's disease active arms list 20 mg capsules.
Half-life & effect duration
- Half-life in the body
- Half-lifeNo settled estimate
- Felt duration people report
- Felt durationNo consistent human-use timeline reported
Cycles people discuss
The public record is a multi-part Phase 1 study, not a copied longevity cycle. Its 28-day safety follow-up window should not be read as 28 days of dosing.
Timing
Timing is study-specific; the notes do not describe a community time-of-day or meal routine. Urolithin A's daily schedule does not transfer to MTX-325.
Stacks
Online wishlists place MTX-325 beside Urolithin A, NMN, MOTS-c or SS-31, but no inspected combination trial or direct multi-agent outcome supports a stack interpretation.
Watch for
Parkinson drug ≠ a longevity stack. Disease-program risk is not mapped for healthy n=1s.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
No numerical human MTX325 half-life is posted in the inspected public study record.
The active Phase 1 arms disclose oral strengths and a PET substudy, but results are not posted. Mouse distribution and target-binding observations describe a different species and endpoint.
Ongoing study, estimated enrollment, no posted results; animal oral bioavailability and brain distribution cannot establish human elimination kinetics.
- ClinicalTrials.gov — Study of MTX325 in Healthy and Parkinson's Disease Participants (opens in a new tab)Current record and API fields: recruiting Phase 1 study, estimated enrollment 106; parts 1–4 list 1.5–100 mg active oral capsules, PET and Parkinson's disease active arms list 20 mg, and safety follow-up is up to 28 days post-dose. No results are posted.Registry protocol rather than results; enrollment is estimated, timing may change, and arm strengths do not specify a consumer regimen or establish exposure-response.
- Nature Communications — Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson's disease mouse model (opens in a new tab)Results and Methods for MTX115325: mouse oral bioavailability about 98%, unbound brain-to-plasma ratio about 0.4, free Cmax at 60 minutes after 10 mg/kg oral dosing and CNS target-binding assessment through eight hours; efficacy dosing included 15 or 50 mg/kg twice daily in mice.Mouse and cell work, not human PK, safety or felt duration; mg/kg animal dosing cannot be converted into a human regimen from this study.
Felt duration people report
No dependable human felt-duration curve was identified.
The registry lists safety and tolerability outcomes but posts no results, and online pipeline discussion is not a participant report.
Absence of posted results and credible direct self-use reports; effects from Urolithin A or other mitochondrial agents cannot be transferred to MTX325.
- ClinicalTrials.gov — Study of MTX325 in Healthy and Parkinson's Disease Participants (opens in a new tab)Current record and API fields: recruiting Phase 1 study, estimated enrollment 106; parts 1–4 list 1.5–100 mg active oral capsules, PET and Parkinson's disease active arms list 20 mg, and safety follow-up is up to 28 days post-dose. No results are posted.Registry protocol rather than results; enrollment is estimated, timing may change, and arm strengths do not specify a consumer regimen or establish exposure-response.
What people say
- “Giga UA” hope: The tweet is stronger mitophagy than a 1 g Mitopure scoop, with CNS reach. That is branding, not a head-to-head trial. forum
- No gym n=1 album. If someone is swallowing a research chem with this name, there is no copied strength or VO2 diary. forum
- Not a stimulant. Mito quality-control pitch, not caffeine. forum
- Parkinson mouse protection: USP30 knockout or MTX in an α-syn model — dopamine terminals held, phospho-α-syn and glia markers down in the Nature Communications write-up people paste. animal
- Human Phase 1a: Company said single/multiple ascending doses in healthy adults were tolerated enough to keep going, with CSF/PET talk that it actually reaches brain. trial
- Fox Foundation / Parkinson’s UK money is why the name keeps showing up in longevity slides. Grant ≠ a result. trial
Doses people talk about
- Do not copy Urolithin A 500–1,000 mg onto MTX-325. Different molecule. forum
- Do not copy SS-31 milligrams onto an oral DUB inhibitor. forum
- Gray-cap math is identity risk, not a protocol. forum
- Framing: No public DIY milligrams. Not a Mitopure scoop with this name on it. forum
- Registered human study arms: Parts 1–4 list active oral capsule strengths from 1.5–100 mg; the PET and Parkinson's disease active arms list 20 mg capsules. These investigational strengths are not a consumer dose chart, and no results are posted. trial
How it may feel
- Now: Pipeline and “why isn’t this on every stack screenshot” posts. forum
- If a gray oral shows up: There is no copied week-1 feel. Do not borrow Mitopure “I didn’t notice anything for a month” lore and stamp this name on it. forum
- Stop: No withdrawal story in biohacker rooms, because almost nobody has a bottle with a history. forum
- Healthy-volunteer clock: SAD/MAD, then elderly cohorts, then PD patients — company timeline, not a feel log. trial
- Parkinson's disease part: The registered study includes adults with mild-to-moderate idiopathic Parkinson's disease and lists safety/tolerability as a primary outcome. No participant results or feel curve are posted. trial
Cycles people discuss
- Forum “cycle”: Doesn’t exist as a copied chart. forum
- Longevity-stack screenshots that list MTX next to UA/NMN are wishlists. forum
- Clinic model: Oral chronic therapy in a PD program — not an 8-week blast. trial
- Phase 1 timing: The registry reports safety follow-up up to 28 days after a dose; that outcome window does not establish a 28-day dosing block. The Parkinson's disease part uses oral MTX325, but its full schedule is not a community cycle. trial
Timing
- No meme human T½ on forums. forum
- UA’s daily 500–1,000 mg clock is not this molecule’s clock. forum
- Downstream: Mitophagy is a chronic-intake story, not a 90-minute pump. forum
- Preclinical distribution, not human half-life: MTX115325 showed roughly 98% oral bioavailability and an unbound brain-to-plasma ratio near 0.4 in mice; one mouse experiment assessed CNS target binding for eight hours. These measurements do not establish human elimination kinetics. animal
More on what it is
- Why people talk about it: Longevity X nicknamed it “giga urolithin” — same mitophagy drawer as Mitopure, pharma-grade, brain-penetrant pitch. Diaries for biohackers are basically none. forum
- Vs Urolithin A: UA is an oral postbiotic with human muscle RCTs at 500–1,000 mg. MTX is a selective DUB inhibitor with Phase 1 PK, not a pomegranate metabolite. forum
- Vs MOTS-c / SS-31: Those are inject mito peptides. This is a small-molecule enzyme block. Same hallway, different door. forum
- What it is: An oral USP30 blocker in a Parkinson’s program (Mission Therapeutics, Cambridge). Company papers also say MTX115325. Swallow, not a pin. trial
- How it works (plain): USP30 sits on mitochondria and peels off the ubiquitin tags that mark junk mito for recycling. Block USP30 → mitophagy stays on. Parkinson’s story is dying dopamine cells with bad mitochondria. trial
- Current clinical context: The public Phase 1 protocol includes healthy-adult SAD, MAD, elderly and PET parts plus a mild-to-moderate Parkinson's disease part. The registry remains recruiting and has no posted results; gray “MTX-325” caps remain an identity risk. trial
Stacks
- Solo pipeline name — not a 2026 gym stack. forum
- Wishlisted next to Urolithin A / NMN / MOTS-c in longevity slide decks. Comparison, not a copied combo trial. forum
- Do not stack mystery USP30 + UA + SS-31 and log it as one mito experiment. forum
Storage notes
- Clinic capsules/tablets, not BAC water. forum
- If a “MTX-325 / MTX115325” research powder appears, treat identity as unproven. forum
Watch for
- Not Urolithin A. Don’t swallow gram scoops and call it this. forum
- Gray-cap identity. forum
- Parkinson drug ≠ a longevity stack. Disease-program risk is not mapped for healthy n=1s. forum
- No posted human results: The registry lists adverse events, vital signs, laboratory safety and ECGs as study outcomes, but no results or adverse-event table are posted. Ongoing-study design is not evidence of tolerability. trial
- Pipeline dates slip. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.